Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
Technology appraisal guidance
Reference number: TA964
Published:
This appraisal has been developed as part of NICE's proportionate approach to technology appraisals. It is a pilot for the ‘Pathways’ approach. (This appraisal was previously referred to as renal cell carcinoma Pathways Pilot [ID6186].)